Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TransMedics Group, Inc. Director's Dealing 2024

Aug 8, 2024

31201_dirs_2024-08-08_eee0da2d-d0c2-4635-8011-00d9c8b81b8e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2024-08-06

Reporting Person: Basile Edward M (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-08-06 Common Stock M 6750 $28.12 Acquired 7482 Direct
2024-08-06 Common Stock S 1830 $148.26 Disposed 5652 Direct
2024-08-06 Common Stock S 2383 $149.71 Disposed 3269 Direct
2024-08-06 Common Stock S 1000 $150.7 Disposed 2269 Direct
2024-08-06 Common Stock S 1537 $151.89 Disposed 732 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-08-06 Stock Option (Right to Buy) $28.12 M 6750 Disposed 2032-06-01 Common Stock (6750) Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $147.76 to $148.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $149.21 to $150.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $150.50 to $151.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $151.80 to $152.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6: The option is fully vested.